Market-Moving News for March 19th
Market-Moving News for March 19th
CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs
CERS：64% | Cerus Corporation宣布其INTERCEPT血液系统的Recepi三期试验已达到其主要疗效终点；截取红细胞在上次输血后28天内出现任何相关治疗-紧急不良事件的患者比例的安全终点没有显著差异
CRNX: 20% | Crinetics Pharmaceuticals shares are trading higher after the company's Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.
CRNX：20% | Crinetics Pharmaceuticals的Paltusotine治疗肢端肥大症的3期 PATHFNDR-2 试验达到了主要终点和所有次要终点后，该公司的股价走高。
HOTH: 60% | Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease.
HOTH：60% | Hoth Therapeutics表示，HT-ALZ已成为对抗与阿尔茨海默氏病相关的神经炎症和认知缺陷的有前途的新型解决方案。